title: Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk population.
abstract: Despite clear association between increased level of homocysteine and increased risk for atherothrombotic events, there is currently not enough evidence to initiate homocysteine-lowering vitamins in high risk population in order to improve cardiovascular outcomes in the light of recent clinical trials. Further large-scale adequately powered clinical trials are awaited to clarify this issue.
authors.forename: Sadik
authors.initials: S
authors.lastname: Acikel
authors.forename: Mehmet
authors.initials: M
authors.lastname: Dogan
authors.forename: Ramazan
authors.initials: R
authors.lastname: Akdemir